SynCore Biotechnology Co., Ltd.

As of June 30, 2026, SynCore Biotechnology Co., Ltd. carries a market capitalization of 705.06M, placing it among publicly traded companies globally. Its enterprise value stands at 571.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SynCore Biotechnology Co., Ltd. has 35.17M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 26.88, and the price-to-book ratio stands at 3.22.

These figures are as of June 30, 2026. The EV/Sales ratio of 21.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 571.78M versus a market cap of 705.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SynCore Biotechnology Co., Ltd. maintains a current ratio of 11.56, meaning it holds 11.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.72, indicating elevated leverage, while an interest coverage ratio of -154.31 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SynCore Biotechnology Co., Ltd. posted a negative return on equity (ROE) of -19.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.77, reflecting losses generated across the asset base. The company generates approximately 709,162.16 in revenue per employee across its workforce of 37.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.61 indicates how many times SynCore Biotechnology Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, SynCore Biotechnology Co., Ltd.'s stock has declined approximately 36.57% over the past 52 weeks. The 50-day moving average sits at 18.75, while the 200-day moving average is 21.33.

Over the twelve months ended June 30, 2026, SynCore Biotechnology Co., Ltd. generated 26.24M in revenue and converted that into -46.85M in net income, yielding earnings per share of -1.33. EBITDA reached -31.32M, while operating income came in at -48.74M.

As of June 30, 2026, SynCore Biotechnology Co., Ltd. holds 145.80M in cash and equivalents against 12.53M in total debt, resulting in a net debt position of -138.69M. Total book value stands at 219.18M, with working capital of 175.94M providing operational flexibility.

SynCore Biotechnology Co., Ltd. produced -32.27M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -477,000.00 in capital expenditures, free cash flow totaled -32.74M - equivalent to -0.93 per share.

Over the twelve months ended June 30, 2026, SynCore Biotechnology Co., Ltd. posted a gross margin of 81.41, reflecting its pricing power and cost economics. The operating margin of -185.77 and net profit margin of -178.54 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SynCore Biotechnology Co., Ltd. shareholders.

SynCore Biotechnology Co., Ltd.'s most recent stock split took place on October 5, 2023 with a 695:706 split ratio.

As of June 30, 2026, SynCore Biotechnology Co., Ltd. has an Altman Z-Score of 20.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.